.

0 (hodnocen0 x )

EB

ONLINE

7th ed.

Philadelphia : Wolters Kluwer Health, 2020

1 online resource (1727 pages)

ISBN 9781975142650 (electronic bk.)

ISBN 9781975142643

Print version: Berek, Jonathan Berek and Hacker’s Gynecologic Oncology Philadelphia : Wolters Kluwer Health,c2020 ISBN 9781975142643

Cover -- Title Page -- Copyright -- Dedication -- Contributors -- Foreword to the First Edition -- Preface -- Contents -- Section I: General Principles -- Chapter 1: Cancer Genetics -- Historic Perspective -- Genetic Changes -- Sporadic -- Hereditary -- Oncogenes -- Types of Oncogenes -- Tumor Suppressor Genes (Anti-Oncogenes) -- Epigenetic Changes -- Genetic Changes in Gynecologic Malignancies -- Endometrial Cancer -- Uterine Mesenchymal Tumors -- Ovarian Cancer -- Ovarian Sex Cord Stromal Tumors -- Cervical Cancer -- Vulvar Cancer -- Gestational Trophoblastic Disease -- Chapter 2: Cancer Cell Biology -- Cell Growth and Proliferation -- Oncogenes -- Tumor Suppressor Genes -- DNA Repair -- DNA Damage Response Defects and Synthetic Lethality to Enhance Efficacy of Cancer Therapy -- Cell Death Pathways -- Autophagy -- Apoptosis -- Necrosis -- Cancer Stem Cells -- Cellular Senescence -- Cell Metabolism -- Hormone Metabolism -- Post-translational Modifications -- Cell Invasion and Metastasis -- Epithelial-to-Mesenchymal Transition -- Tumor Microenvironment -- Immune Checkpoints -- Angiogenesis -- Biomarkers -- Tumor Markers -- Chapter 3: Biologic, Targeted, and Immune Therapy -- Inhibitors of Growth Factor Receptors -- EGFR Inhibitors -- EGFR Inhibitors-Small Molecules -- EGFR Inhibitors-Monoclonal Antibodies -- Her2/Neu Inhibitors -- Her2/Neu Inhibitors-Small Molecules -- Her2/Neu Inhibitors-Monoclonal Antibodies -- PDGFR Inhibitors-Monoclonal Antibodies -- Inhibitors of Angiogenesis -- VEGFR Inhibitors-Small Molecules -- VEGFR Inhibitors-Monoclonal Antibodies -- Inhibitors of Other Intracellular Kinases -- Small Molecules -- Braf (Rapidly Activated Fibrosarcoma) Inhibitors -- MEK1-2 (MAPK/ERK Kinase) Inhibitors -- CDK 4-6 (Cyclin-Dependent Kinases 4-6) Inhibitors -- ALK (Anaplastic Lymphoma Kinase) Inhibitors.

Chapter 7: Epidemiology and Biostatistics -- Descriptive Statistics -- Incidence -- Prevalence -- Cancer Survival -- Etiologic Studies -- Case-Control Study -- Cohort Studies -- Statistical Inference and Validity -- Statistical Inference -- Statistical Distributions and Tests -- Validity -- Other Criteria for Judging an Epidemiologic Study -- Cancer Risk and Prevention -- Cervical Cancer -- Endometrial Cancer -- Ovarian Cancer -- Other Gynecologic Neoplasms -- Cancer Prevention -- Secondary Prevention -- Test Definitions -- Sensitivity -- Specificity -- Predictive Value -- Screening Strategies -- Section II: Disease Sites -- Chapter 8: Preinvasive Disease -- Cervix -- Classification of Preinvasive Cervical Disease -- Understanding the Cervical Transformation Zone -- IFCPC Colposcopic Terminology of the Cervix, Vagina, and Vulva -- Systematic Approach to Colposcopy -- Indications for Colposcopy -- Human Papillomaviruses and Cervical Neoplasia -- Human Papillomavirus Vaccines -- The WHO Initiative for the Elimination of Cervical Cancer as a Public Health Problem -- Screening for Cervical Neoplasia -- Treatment of Cervical Intraepithelial Neoplasia -- Treatment Modalities -- Vagina -- Classification of Vaginal Intraepithelial Neoplasia -- Clinical Profile -- Diagnosis -- Treatment of High-Grade Vaginal Intraepithelial Neoplasia -- Vulva and Perianal Area -- Classification -- Paget Disease -- Clinical Profile of High-Grade Vulvar Intraepithelial Neoplasia (uVIN) -- Diagnosis -- Natural History of High-Grade Vulvar Intraepithelial Neoplasia -- Differentiated Vulvar Intraepithelial Neoplasia (dVIN) -- Treatment of High-Grade Vulvar Intraepithelial Neoplasia -- HPV Vaccination -- Multicentric Lower Genital Tract Neoplasia -- Chapter 9: Cervical Cancer -- Diagnosis -- Symptoms -- Signs -- Biopsy -- Colposcopy for Invasive Cancer -- Staging.

Noninvasive Diagnostic Studies -- Surgical Staging -- Patterns of Spread -- Direct Infiltration -- Lymphatic Spread -- Hematogenous Spread -- Treatment -- Microinvasive Carcinoma -- 2018 FIGO Stages IB1, IB2, and Early-Stage IIA1 Cervical Cancer -- Stage IB3 Cervical Carcinoma -- Prognostic Factors for Stages IB to IIA -- Stages IIB to IVA Disease -- Nonsquamous Histologic Types -- Adenocarcinoma -- Adenosquamous Carcinoma -- Glassy Cell Carcinoma -- Adenoma Malignum (Minimum Deviation Adenocarcinoma) -- Adenoid Cystic Carcinoma -- Adenoid Basal Carcinoma -- Clear Cell Adenocarcinoma -- Villoglandular Papillary Adenocarcinoma -- Small-Cell, including Small-Cell Neuroendocrine Carcinoma -- Large-Cell Neuroendocrine Carcinoma -- Serous Carcinoma -- Sarcoma -- Lymphoma -- Verrucous Carcinoma -- Melanoma -- Metastatic Carcinoma -- Cancer of the Cervical Stump -- Invasive Cancer Found after Simple Hysterectomy -- Coexistent Pelvic Mass -- Cervical Bleeding -- Recurrent Cervical Cancer -- Radical Hysterectomy for Recurrence -- Chemotherapy -- Chapter 10: Uterine Cancer -- Prevention of Disease and Screening of Asymptomatic Women -- Clinical Features -- Symptoms -- Signs -- Diagnosis -- Preoperative Investigations -- Staging -- Spread Patterns -- Prognostic Variables -- Age -- Histologic Type -- Histologic Grade and Myometrial Invasion -- Vascular Space Invasion -- Results of Peritoneal Cytology -- Hormone Receptor Status -- Nuclear Grade -- Tumor Size -- DNA Ploidy and Other Biologic Markers -- Body Mass Index -- Method of Treatment -- Endometrial Hyperplasia -- Diagnosis -- Treatment -- Treatment of Endometrial Cancer -- Stage I and Stage II Occult -- Clinical Stage II -- Surgical Stage IIIA -- Surgical Stage IIIB -- Surgical Stage IVA -- Surgical Stage IVB -- Special Clinical Circumstances -- Recurrent Endometrial Cancer -- Isolated Vaginal Recurrence.

Treatment Strategies to Exploit Differences Between Tumor and Normal Tissue in the Response to Fractionated Radiation Therapy -- Combinations of Surgery and Radiation Therapy -- Physical Principles -- Ionizing Radiations Used in Therapy -- Interactions of Radiation With Matter -- Measurement of Absorbed Dose -- Inverse Square Law -- Radiation Techniques -- External Beam Irradiation -- Brachytherapy -- Palliation -- Chapter 6: Pathology -- Cervix -- Squamous Lesions of the Cervix -- Human Papilloma Virus -- Cervicovaginal Cytology-Pap Testing -- Glandular Lesions of the Cervix -- Mesenchymal Tumors -- Vagina -- Squamous Lesions of the Vagina -- Glandular Lesions of the Vagina -- Fibroepithelial Stromal Polyp -- Sarcoma Botryoides -- Melanoma -- Postoperative Spindle Cell Nodule -- Vulva -- Squamous Cell Lesions of the Vulva -- Other Vulvar Lesions -- Mesenchymal Tumors -- Aggressive Angiomyxoma -- Melanocytic Tumors -- Uncommon Neoplasms -- Uterine Corpus -- Endometrial Neoplasms -- Endometrial Carcinoma -- Histologic Types -- Histologic Grading of Endometrioid Carcinoma -- Pathologic Staging of Endometrial Carcinoma -- Mesenchymal Neoplasms -- Uterine Tumor Resembling Ovarian Sex Cord-Stromal Tumor -- Endometrial Stromal Tumors -- Undifferentiated Uterine Sarcoma -- Other Uterine Mesenchymal Tumors -- Mixed Mullerian Neoplasms -- Adenofibroma -- Atypical Polypoid Adenomyoma -- Adenosarcoma -- Carcinosarcoma -- Ovary -- Ovarian Epithelial Tumors -- Sex Cord-Stromal Tumors -- Germ Cell Tumors -- Embryonal Carcinoma -- Miscellaneous Ovarian Tumors -- Secondary Tumors of the Ovary-Metastases -- Nonneoplastic Lesions of the Ovary -- Luteinized Ovarian Conditions -- Fallopian Tube -- Primary Tubal Carcinoma -- Adenomatoid Tumor -- Gestational Trophoblastic Disease -- Hydatidiform Mole -- Choriocarcinoma -- Placental Site Trophoblastic Tumor.

Nodal Recurrence.

PI-3K (Phosphatidylinositol 3-Kinase) Inhibitors -- mTOR (Mammalian Target of Rapamycin) Inhibitors -- Inhibitors of DNA Repair -- PARP (Poly-ADP Ribose-Polymerase) Inhibitors -- Immunotherapy -- Cytokines -- Monoclonal Antibodies -- Immune Checkpoint Inhibitors -- Anti-PD-1 (Programmed Cell Death Receptor-1) Antibodies -- Anti-PD-L1 (Programmed Cell Death Receptor Ligand-1) Antibodies -- Therapeutic Cancer Vaccines -- Cell-Based Vaccines -- Glycan-Based Vaccines -- Adoptive Cell Therapy -- Chapter 4: Chemotherapy -- General Principles -- Tumor Growth and Chemotherapy -- Differential Sensitivity -- Therapeutic Index -- Brief History of Chemotherapy -- Biologic Factors Influencing Treatment -- Cell Kinetic Concepts -- Cancer Cell Growth -- Principles of Chemotherapy -- Neoadjuvant Chemotherapy -- Hyperthermic Intraperitoneal Chemotherapy -- Antibody-Drug Conjugates -- Chemotherapy in Pregnancy -- Drug Resistance -- Excretion -- Drug Interactions -- Combination Chemotherapy -- Clinical Benefit -- RECIST Criteria -- Dose Adjustment -- Carboplatin Dose Calculation -- Toxicities and Their Management -- Antineoplastic Drugs -- Alkylating Agents -- Antitumor Antibiotics and Topoisomerase Inhibitors -- Antimetabolites -- Plant Alkaloids (Mitotic Spindle Agents) -- Chapter 5: Radiation Therapy -- Radiation Biology -- Radiation Damage and Repair -- Cell Survival Curves -- Fractionation -- Dose-Rate Effect -- The Four Rs -- Treatment Strategies for Overcoming Radioresistance of Hypoxic Cells -- Linear-Energy Transfer and Relative Biologic Effectiveness -- Hyperthermia -- Interactions between Radiation and Drugs -- Radiation Therapy and the Immune System -- Therapeutic Ratio -- Effects of Radiation on Normal Tissues -- Scoring of Late Complications of Radiation Therapy.

001905307

express

(Au-PeEL)EBL6743421

(MiAaPQ)EBC6743421

(OCoLC)1273976376